Research

Hormonal

Combining the amylin analog pramlintide with the leptin analog metreleptin produces significantly greater weight loss in obese humans than either agent alone, primarily by synergistically enhancing fat loss and mitigating metabolic counter-regulation.

For obese or overweight individuals without diabetes, combining pramlintide and metreleptin offers significantly better weight loss than using either drug alone. The regimen involves twice-daily subcutaneous injections taken before meals, alongside a moderate caloric deficit. While side effects like nausea and injection site reactions occur, they tend to be mild and diminish over time. This approach is particularly useful for those who experience weight loss plateaus with standard therapies.

GoodSupportsHIGH confidence
Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (−12.7 ± 0.9%; least squares mean ± s.e.) than treatment with pramlintide (−8.4 ± 0.9%; P < 0.001) or metreleptin (−8.2 ± 1.3%; P < 0.01) alone
Éric Ravussin et al. · Obesity · 2009

Why this rating

Randomized, double-blind, active-drug-controlled clinical trial with a moderate sample size (N=177, evaluable N=93).

Source

Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy

Éric Ravussin et al. · Obesity · 2009

DOI 10.1038/oby.2009.184

rct · n=177Cited 327×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →